Korean Circ J.  2022 Jun;52(6):475-477. 10.4070/kcj.2022.0126.

On-Treatment Diastolic Blood Pressure: When Is It Too High?

• Park JJ

• KMID: 2530456
• DOI: http://doi.org/10.4070/kcj.2022.0126

Reference

1. Kim HC, Lee H, Lee HH, et al. Korea hypertension fact sheet 2021: analysis of nationwide population-based data with special focus on hypertension in women. Clin Hypertens. 2022; 28:1. PMID: 34980274.

2. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002; 360:1903–1913. PMID: 12493255.

3. Cheung BM, Or B, Fei Y, Tsoi MF. A 2020 vision of hypertension. Korean Circ J. 2020; 50:469–475. PMID: 32281321.

4. SPRINT Research Group. Wright JT Jr, Williamson JD, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015; 373:2103–2116. PMID: 26551272.

5. Shin J, Cho MC. Updated reasons and clinical implications of new Korean hypertension guidelines for cardiologists. Korean Circ J. 2020; 50:476–484. PMID: 32281319.

6. Kim DH, Cho IJ, Kim W, et al. Elevated on-treatment diastolic blood pressure and cardiovascular outcomes in the presence of achieved systolic blood pressure targets. Korean Circ J. 2022; 52:460–474.

7. ACCORD Study Group. Cushman WC, Evans GW, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010; 362:1575–1585. PMID: 20228401.

8. Lonn EM, Bosch J, López-Jaramillo P, et al. Blood-pressure lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med. 2016; 374:2009–2020. PMID: 27041480.

9. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009; 338:b1665. PMID: 19454737.